Soligenix's orBec misses GvHD endpoint

Soligenix Inc. (OTCBB:SNGX) said orBec beclomethasone dipropionate missed the primary endpoint in a Phase II trial to prevent acute graft-versus-host disease (GvHD) after hematopoietic stem cell transplantation (HSCT). The oral corticosteroid did not significantly reduce the proportion of patients who developed acute GvHD with severity sufficient to require systemic immunosuppressive treatment within 90 days of HSCT vs. placebo. The double-blind, U.S. trial enrolled 140 patients. ...